CASI doses first patient in Phase 1/2 CID-103 trial for renal allograft antibody-mediated rejection in China

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

CASIF

0.00
  • CASI Pharmaceuticals dosed the first patient in a Phase 1/2 trial of CID-103 for active or chronic active renal allograft antibody-mediated rejection in China.
  • No results have been presented; the study is designed to generate future safety, tolerability, and dose-response data.
  • CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody; the program targets organ transplant rejection and autoimmune diseases.
  • CASI also has FDA IND clearance to run a Phase 1 renal allograft antibody-mediated rejection study in the US.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.